MSD

News

Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.

News

The VOLGA trial shows that Imfinzi and Padcev could be a rival Keytruda+Padcev in perioperative treatment of muscle-invasive bladder cancer.

News

Moderna and MSD shared the results for their melanoma cancer vaccine trial, ahead of a presentation at ESMO tomorrow, after a data breach.

News

In its decanting of the BRUNELLO trial of remigromig for diabetic macular oedema, MSD seems to have left observers contemplating a glass half empty.

News

MSD has been rocked by a court judgment ordering it to stop making and selling subcutaneous Keytruda in eight European markets.

News

Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.